OmniAb
OABI
4.31
-0.26
-5.59%
OmniAb
US · OABI
#3556 by market cap
Listed 2021
4.31
-0.26
-5.59%
Live - 5344 symbols - heartbeat 394s ago
· 2026-10-08 10:00
Pre-market
4.25
-6.80%
After-hours
4.61
+1.10%
- Market cap
- 625.91M
- P/E (TTM)i
- -11.96
- P/Bi
- 2.41
- EPSi
- -0.57
- Div yieldi
- 0.00%
- 52W posi
- 73%
Reader sentiment
Are you bullish or bearish on OABI?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 9.81, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 7 years
Latest year -29.27% YoY
Margins
- Gross margin
- 98.38%
- Operating margin
- -369.49%
- Net margin
- -347.04%
Key ratios & quality
- Altman Z-Scorei
- 9.81
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 18.32M | 23.27M | 34.75M | 59.08M | 34.16M | 26.39M | 18.67M |
| Gross profit | -- | -- | -- | -- | -- | 26.39M | 18.36M |
| Selling & admin expenses | 8.65M | 10.23M | 16.95M | 24.90M | 33.31M | 30.74M | 29.22M |
| Research & development | 13.21M | 24.80M | 39.23M | 48.36M | 56.53M | 55.11M | 47.75M |
| Operating profit | -13.03M | -25.62M | -35.61M | -26.65M | -69.42M | -74.50M | -68.97M |
| Pretax profit | -13.03M | -23.73M | -34.35M | -26.06M | -64.36M | -71.41M | -66.29M |
| Tax | 562.00K | -6.17M | -7.31M | -3.73M | -13.74M | -9.38M | -1.52M |
| Net profit | -13.59M | -17.56M | -27.04M | -22.33M | -50.62M | -62.03M | -64.78M |
| Basic EPS | 0 | 0 | 0 | 0 | -1 | -1 | -1 |
| Diluted EPS | -0.12 | -0.15 | -0.24 | -0.26 | -0.51 | -0.61 | -0.57 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 4.15M | 3.90M | 2.24M | 8.38M | 14.43M | 13.42M |
| Gross profit | 4.15M | 3.64M | 2.21M | 8.37M | 14.41M | 12.81M |
| Selling & admin expenses | 7.92M | 7.68M | 6.78M | 6.84M | 6.62M | 6.65M |
| Research & development | 12.60M | 10.86M | 10.38M | 13.91M | 9.64M | 9.59M |
| Operating profit | -18.84M | -19.22M | -18.14M | -15.77M | -7.83M | -6.64M |
| Pretax profit | -18.31M | -15.76M | -17.69M | -14.55M | -7.27M | -6.21M |
| Tax | -106.00K | 119.00K | -1.16M | -367.00K | 442.00K | -353.00K |
| Net profit | -18.20M | -15.88M | -16.53M | -14.18M | -7.71M | -5.86M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | -0.17 | -0.15 | -0.14 | -0.11 | -0.06 | -0.05 |
Balance sheet
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Total current assets | -- | 16.65M | 22.54M | 124.95M | 94.90M | 68.14M | 65.34M |
| Cash & ST investments | -- | -- | 0 | 88.27M | 86.98M | 59.43M | 54.03M |
| Inventory | -- | -- | -- | -- | -- | -- | -- |
| Total assets | -- | 295.38M | 304.47M | 421.21M | 375.23M | 325.56M | 300.91M |
| Total current liabilities | -- | 14.28M | 20.58M | 26.02M | 23.12M | 15.09M | 16.25M |
| Short-term debt | -- | 580.00K | 578.00K | 1.78M | 3.49M | 3.78M | 3.88M |
| Long-term debt | -- | -- | -- | -- | -- | -- | -- |
| Total liabilities | -- | 59,843,000.00 | 70,158,000.00 | 79,839,000.00 | 60,640,000.00 | 37,940,000.00 | 33,887,000.00 |
| Total equity | -- | 235.54M | 234.31M | 341.37M | 314.59M | 287.62M | 267.03M |
| Retained earnings | -- | -- | 0 | 11.25M | -39.37M | -101.40M | -166.18M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 53.58M | 47.62M | 66.35M | 65.34M | 65.13M | 66.01M |
| Cash & ST investments | 43.60M | 41.62M | 59.50M | 54.03M | 49.07M | 52.00M |
| Inventory | -- | -- | 443.00K | -- | 920.00K | 1.01M |
| Total assets | 306.18M | 295.67M | 309.69M | 300.91M | 293.65M | 290.26M |
| Total current liabilities | 11.41M | 12.64M | 13.28M | 16.25M | 13.57M | 13.76M |
| Short-term debt | 3.81M | 3.84M | 3.86M | 3.88M | 3.94M | 3.97M |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 32,666,000.00 | 33,610,000.00 | 32,246,000.00 | 33,887,000.00 | 31,004,000.00 | 29,983,000.00 |
| Total equity | 273.52M | 262.06M | 277.44M | 267.03M | 262.65M | 260.27M |
| Retained earnings | -119.60M | -135.48M | -152.00M | -166.18M | -173.89M | -179.75M |
Cash flow
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -5.20M | 3.62M | -5.67M | -3.59M | 2.35M | -39.66M | -36.46M |
| Depreciation & amortization | 10.92M | 13.14M | 16.25M | 18.25M | 19.50M | 23.58M | 21.75M |
| Free cash flow | -5.45M | 1.87M | -9.74M | -20.76M | 703.00K | -41.54M | -37.02M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | 0 | 96.24M | 0 | 11.37M | 28.20M |
| Ending cash balance | 0 | 0 | 0 | 33.84M | 16.92M | 28.16M | 26.08M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -15.87M | -5.15M | -9.76M | -5.67M | -4.91M | 2.68M |
| Depreciation & amortization | 4.74M | 4.65M | 4.66M | 7.71M | 7.21M | 4.22M |
| Free cash flow | -16.08M | -5.31M | -9.95M | -5.68M | -5.08M | 2.57M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | 0 | -- | -- |
| Ending cash balance | 11.45M | 18.84M | 29.10M | 26.08M | 29.61M | 24.90M |
Returns & efficiency
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| ROE %i | -- | -7.45 | -11.51 | -7.76 | -15.43 | -20.60 | -23.36 |
| ROA %i | -- | -5.94 | -9.02 | -6.16 | -12.71 | -17.70 | -20.68 |
| ROIC %i | -- | -7.37 | -11.12 | -7.42 | -15.44 | -19.89 | -22.53 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -12.55 | -15.73 |
| EBIT margin %i | -71.12 | -101.96 | -98.83 | -44.11 | -203.19 | -282.30 | -369.49 |
| FCF / sales %i | -- | 8.02 | -- | -- | 2.06 | -- | -- |
| Current ratioi | -- | 1.17 | 1.10 | 4.80 | 4.11 | 4.52 | 4.02 |
| Quick ratioi | -- | 1.11 | 1.03 | 4.56 | 3.93 | 4.29 | 3.78 |
| Debt / assetsi | -- | 0.88 | 4.55 | 6.12 | 6.81 | 7.12 | 6.76 |
| LT debt / equityi | -- | 0.85 | 5.66 | 7.04 | 7.02 | 6.74 | 6.16 |
| Interest coveragei | -- | -4,744.60 | -4,906.14 | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | 47.75 | 13.66 | -8.76 | -31.89 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -27.78 | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -21.32 | -22.84 | -22.37 | -23.36 | -20.25 | -16.95 |
| ROA %i | -18.60 | -20.07 | -19.86 | -20.68 | -18.10 | -15.11 |
| ROIC %i | -20.46 | -21.80 | -21.38 | -22.53 | -19.66 | -16.62 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -264.71 | -320.09 | -327.50 | -369.49 | -200.26 | -117.98 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 4.70 | 3.77 | 5.00 | 4.02 | 4.80 | 4.80 |
| Quick ratioi | 4.39 | 3.51 | 4.71 | 3.78 | 4.55 | 4.53 |
| Debt / assetsi | 7.34 | 7.37 | 6.80 | 6.76 | 6.70 | 6.52 |
| LT debt / equityi | 6.82 | 6.85 | 6.20 | 6.16 | 5.99 | 5.74 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Providing discovery research technology to enable the discovery of next-generation therapeutics100.00%
Quote time 2026-10-08 10:00:03 · For reference only, not investment advice and not tailored to your situation.